We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

4 hedge funds and large institutions have $4.15M invested in Intra-Cellular Therapies Inc. in 2025 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 0 increasing their positions, 2 reducing their positions, and 389 closing their positions.

New
Increased
Maintained
Reduced
Closed

99% less funds holding

Funds holding: 395 → 4 (-391)

100% less capital invested

Capital invested by funds: $13.6B → $4.15M (-$13.6B)

100% less funds holding in top 10

Funds holding in top 10: 52 → 0 (-52)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 389

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
4
Holders Change
-391
Holders Change %
-98.99%
% of All Funds
0.05%
Holding in Top 10
–
Holding in Top 10 Change
-52
Holding in Top 10 Change %
-100%
% of All Funds
–
New
–
Increased
–
Reduced
2
Closed
389
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$1.26B
2
BlackRock
BlackRock
New York
-$1.15B
3
PCM
Pentwater Capital Management
Florida
-$685M
4
HI
HBK Investments
Texas
-$578M
5
Norges Bank
Norges Bank
Norway
-$472M
Name Holding Trade Value Shares
Change 		Change in
Stake
Janney Montgomery Scott
276
Janney Montgomery Scott
Pennsylvania
– -$421K -3,191 Closed
AI
277
AdvisorShares Investments
Maryland
– -$406K -3,077 Closed
CIBC Asset Management
278
CIBC Asset Management
Ontario, Canada
– -$398K -3,016 Closed
ECM
279
Everence Capital Management
Indiana
– -$394K -2,990 Closed
BC
280
Bayforest Capital
United Kingdom
– -$393K -2,980 Closed
JIP
281
Jaffetilchin Investment Partners
Florida
– -$392K -2,972 Closed
CTC
282
Cetera Trust Company
Minnesota
– -$390K -2,955 Closed
PA
283
Profund Advisors
Maryland
– -$384K -2,911 Closed
Corient Private Wealth
284
Corient Private Wealth
Florida
– -$378K -2,862 Closed
DIG
285
DeepCurrents Investment Group
New York
– -$372K -2,822 Closed
MFG
286
Merit Financial Group
Georgia
– -$369K -2,798 Closed
GFM
287
GF Fund Management
China
– -$358K -2,714 Closed
PNC Financial Services Group
288
PNC Financial Services Group
Pennsylvania
– -$332K -2,516 Closed
Rafferty Asset Management
289
Rafferty Asset Management
New York
– -$328K -2,484 Closed
CB
290
Commerce Bank
Missouri
– -$321K -2,431 Closed
A
291
AlphaQuest
New York
– -$319K -2,421 Closed
Sumitomo Mitsui Trust Group
292
Sumitomo Mitsui Trust Group
Japan
– -$318K -2,407 Closed
Nisa Investment Advisors
293
Nisa Investment Advisors
Missouri
– -$293K -2,224 Closed
AFG
294
Atomi Financial Group
New York
– -$292K -2,216 Closed
Kovitz Investment Group Partners
295
Kovitz Investment Group Partners
Illinois
– -$290K -2,202 Closed
US Bancorp
296
US Bancorp
Minnesota
– -$290K -2,195 Closed
BP
297
Ballentine Partners
Massachusetts
– -$288K -2,180 Closed
Brown Advisory
298
Brown Advisory
Maryland
– -$283K -2,147 Closed
XT
299
XTX Topco
Cayman Islands
– -$275K -2,085 Closed
Comerica Bank
300
Comerica Bank
Texas
– -$266K -2,019 Closed
10 11
12
13 14

ITCI Hedge Fund Activity: Q2 2025 in Review

4 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q2 2025, worth a combined $4.15M — down 100% from $13.6B a quarter earlier.

Sellers outnumbered buyers: 389 funds closed out of ITCI and 0 opened new positions — a net loss of 389 holders — while 2 trimmed existing stakes and 0 added.

The largest seller was Vanguard Group, exiting entirely with an estimated $1.26B sold.

  • 4 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q2 2025, down from 395 in Q1 2025.
  • Funds reported $4.15M of Intra-Cellular Therapies Inc. stock for Q2 2025, down 100% quarter-over-quarter.
  • 0 funds opened new Intra-Cellular Therapies Inc. positions in Q2 2025 and 389 closed out, a net change of -389 holders.
  • The largest Intra-Cellular Therapies Inc. seller in Q2 2025 was Vanguard Group, an estimated $1.26B sold.

Based on aggregated 13F filings for Q2 2025.